SOW
ARQT icon

State of Wyoming’s Arcutis Biotherapeutics ARQT Stock Holding History

State of Wyoming’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$265K Sell
10,088
-8,346
-45% -$194K 0.03% 780
2026
Q1 		$434K Buy
18,434
+7,117
+63% +$182K 0.05% 412
2025
Q4 		$329K Buy
11,317
+7,020
+163% +$180K 0.04% 659
2025
Q3 		$81K Sell
4,297
-8,101
-65% -$128K 0.01% 1371
2025
Q2 		$174K Sell
12,398
-834
-6% -$11.7K 0.02% 1018
2025
Q1 		$207K Buy
13,232
+9,204
+229% +$130K 0.03% 778
2024
Q4 		$56.1K Sell
4,028
-150
-4% -$1.64K 0.01% 1370
2024
Q3 		$38.9K Buy
4,178
+385
+10% +$3.8K 0.01% 1516
2024
Q2 		$35.3K Buy
3,793
+249
+7% +$2.25K 0.01% 1460
2024
Q1 		$35.1K Sell
3,544
-56
-2% -$418 0.01% 1462
2023
Q4 		$11.6K Buy
3,600
+451
+14% +$1.23K ﹤0.01% 1552
2023
Q3 		$16.7K Buy
3,149
+1,298
+70% +$11K ﹤0.01% 1513
2023
Q2 		$17.6K Buy
1,851
+780
+73% +$8.66K 0.01% 1431
2023
Q1 		$11.8K Buy
1,071
+334
+45% +$4.83K ﹤0.01% 1476
2022
Q4 		$10.9K Buy
737
+332
+82% +$5.8K ﹤0.01% 1449
2022
Q3 		$8K Buy
+405
New +$9.18K ﹤0.01% 1438

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Frazier Life Sciences Management
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Rubric Capital Management (New York)
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Polar Capital Holdings
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

State of Wyoming's ARQT Position: Q2 2026 in Review

State of Wyoming reduced its Arcutis Biotherapeutics (ARQT) stake by 45% in Q2 2026, selling an estimated $194K and leaving 10,088 shares worth $265K. The position accounts for 0.03% of the portfolio, ranked #780.

State of Wyoming first reported a position in ARQT in Q3 2022 and has held it in 16 quarters since. The position peaked at $434K in Q1 2026. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • State of Wyoming held 10,088 shares of Arcutis Biotherapeutics worth $265K as of Q2 2026.
  • State of Wyoming sold 8,346 Arcutis Biotherapeutics shares in Q2 2026, an estimated $194K.
  • Arcutis Biotherapeutics made up 0.03% of State of Wyoming's portfolio in Q2 2026, its #780 holding.
  • State of Wyoming first reported a position in Arcutis Biotherapeutics in Q3 2022 and has held it in 16 quarters since.
  • State of Wyoming's Arcutis Biotherapeutics position peaked at $434K in Q1 2026.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on State of Wyoming's 13F filing for Q2 2026, filed 6 Aug 2026.